10.1016/j.febslet.2006.04.010 23
Does Empagliflozin Reduce Diabetes-Related Blindness
GIP Agonism Reduces appetite, nausea, and bone resorption Increases insulin & glucagon production, and lipogenesis Glucagon Agonism Reduces appetite, food intake, and gastric emptying Increases insulin production, energy expenditure, and nausea Amylin Agonism Reduces appetite, food intake, glucagon production, and gastric emptying Increases energy expenditure Reduces bone resorption and increases bone production PYY Agonism Reduces appetite, food intake, and gastric emptying Increases energy expenditure and nausea The Cost Challenge for Payers The cost of GLP-1s continues to be a significant concern for payers between skyrocketing costs and utilization over the past several years
The Novo Nordisk "Direct Pay" Option: For those without insurance coverage or those who prefer to bypass the "red tape" of prior authorizations, Novo Nordisk has introduced a direct-to-consumer pharmacy model
The outcomes you're targeting
Well-established dosing protocols